Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals

Bing Mae Chen, Yu Cheng Su, Chia Jung Chang, Pierre Alain Burnouf, Kuo-Hsiang Chuang, Chien Hsiun Chen, Tian Lu Cheng, Yuan Tsong Chen, Jer Yuarn Wu, Steve R. Roffler

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Polyethylene glycol (PEG) is a biocompatible polymer that is often attached to therapeutic molecules to improve bioavailability and therapeutic efficacy. Although antibodies with specificity for PEG may compromise the safety and effectiveness of PEGylated medicines, the prevalence of pre-existing anti-PEG antibodies in healthy individuals is unclear. Chimeric human anti-PEG antibody standards were created to accurately measure anti-PEG IgM and IgG antibodies by direct ELISA with confirmation by a competition assay in the plasma of 1504 healthy Han Chinese donors residing in Taiwan. Anti-PEG antibodies were detected in 44.3% of healthy donors with a high prevalence of both anti-PEG IgM (27.1%) and anti-PEG IgG (25.7%). Anti-PEG IgM and IgG antibodies were significantly more common in females as compared to males (32.0% vs 22.2% for IgM, p < 0.0001 and 28.3% vs 23.0% for IgG, p = 0.018). The prevalence of anti-PEG IgG antibodies was higher in younger (up to 60% for 20 year olds) as opposed to older (20% for >50 years) male and female donors. Anti-PEG IgG concentrations were negatively associated with donor age in both females (p = 0.0073) and males (p = 0.026). Both anti-PEG IgM and IgG strongly bound PEGylated medicines. The described assay can assist in the elucidation of the impact of anti-PEG antibodies on the safety and therapeutic efficacy of PEGylated medicines.

Original languageEnglish
Pages (from-to)10661-10666
Number of pages6
JournalAnalytical Chemistry
Volume88
Issue number21
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Immunoglobulin M
Immunoglobulin G
Antibodies
Medicine
Assays
Polymers
Plasmas
Molecules

ASJC Scopus subject areas

  • Analytical Chemistry

Cite this

Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. / Chen, Bing Mae; Su, Yu Cheng; Chang, Chia Jung; Burnouf, Pierre Alain; Chuang, Kuo-Hsiang; Chen, Chien Hsiun; Cheng, Tian Lu; Chen, Yuan Tsong; Wu, Jer Yuarn; Roffler, Steve R.

In: Analytical Chemistry, Vol. 88, No. 21, 01.11.2016, p. 10661-10666.

Research output: Contribution to journalArticle

Chen, BM, Su, YC, Chang, CJ, Burnouf, PA, Chuang, K-H, Chen, CH, Cheng, TL, Chen, YT, Wu, JY & Roffler, SR 2016, 'Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals', Analytical Chemistry, vol. 88, no. 21, pp. 10661-10666. https://doi.org/10.1021/acs.analchem.6b03109
Chen, Bing Mae ; Su, Yu Cheng ; Chang, Chia Jung ; Burnouf, Pierre Alain ; Chuang, Kuo-Hsiang ; Chen, Chien Hsiun ; Cheng, Tian Lu ; Chen, Yuan Tsong ; Wu, Jer Yuarn ; Roffler, Steve R. / Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. In: Analytical Chemistry. 2016 ; Vol. 88, No. 21. pp. 10661-10666.
@article{3468019c43d04fe0a59359b583c943df,
title = "Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals",
abstract = "Polyethylene glycol (PEG) is a biocompatible polymer that is often attached to therapeutic molecules to improve bioavailability and therapeutic efficacy. Although antibodies with specificity for PEG may compromise the safety and effectiveness of PEGylated medicines, the prevalence of pre-existing anti-PEG antibodies in healthy individuals is unclear. Chimeric human anti-PEG antibody standards were created to accurately measure anti-PEG IgM and IgG antibodies by direct ELISA with confirmation by a competition assay in the plasma of 1504 healthy Han Chinese donors residing in Taiwan. Anti-PEG antibodies were detected in 44.3{\%} of healthy donors with a high prevalence of both anti-PEG IgM (27.1{\%}) and anti-PEG IgG (25.7{\%}). Anti-PEG IgM and IgG antibodies were significantly more common in females as compared to males (32.0{\%} vs 22.2{\%} for IgM, p < 0.0001 and 28.3{\%} vs 23.0{\%} for IgG, p = 0.018). The prevalence of anti-PEG IgG antibodies was higher in younger (up to 60{\%} for 20 year olds) as opposed to older (20{\%} for >50 years) male and female donors. Anti-PEG IgG concentrations were negatively associated with donor age in both females (p = 0.0073) and males (p = 0.026). Both anti-PEG IgM and IgG strongly bound PEGylated medicines. The described assay can assist in the elucidation of the impact of anti-PEG antibodies on the safety and therapeutic efficacy of PEGylated medicines.",
author = "Chen, {Bing Mae} and Su, {Yu Cheng} and Chang, {Chia Jung} and Burnouf, {Pierre Alain} and Kuo-Hsiang Chuang and Chen, {Chien Hsiun} and Cheng, {Tian Lu} and Chen, {Yuan Tsong} and Wu, {Jer Yuarn} and Roffler, {Steve R.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1021/acs.analchem.6b03109",
language = "English",
volume = "88",
pages = "10661--10666",
journal = "Analytical Chemistry",
issn = "0003-2700",
publisher = "American Chemical Society",
number = "21",

}

TY - JOUR

T1 - Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals

AU - Chen, Bing Mae

AU - Su, Yu Cheng

AU - Chang, Chia Jung

AU - Burnouf, Pierre Alain

AU - Chuang, Kuo-Hsiang

AU - Chen, Chien Hsiun

AU - Cheng, Tian Lu

AU - Chen, Yuan Tsong

AU - Wu, Jer Yuarn

AU - Roffler, Steve R.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Polyethylene glycol (PEG) is a biocompatible polymer that is often attached to therapeutic molecules to improve bioavailability and therapeutic efficacy. Although antibodies with specificity for PEG may compromise the safety and effectiveness of PEGylated medicines, the prevalence of pre-existing anti-PEG antibodies in healthy individuals is unclear. Chimeric human anti-PEG antibody standards were created to accurately measure anti-PEG IgM and IgG antibodies by direct ELISA with confirmation by a competition assay in the plasma of 1504 healthy Han Chinese donors residing in Taiwan. Anti-PEG antibodies were detected in 44.3% of healthy donors with a high prevalence of both anti-PEG IgM (27.1%) and anti-PEG IgG (25.7%). Anti-PEG IgM and IgG antibodies were significantly more common in females as compared to males (32.0% vs 22.2% for IgM, p < 0.0001 and 28.3% vs 23.0% for IgG, p = 0.018). The prevalence of anti-PEG IgG antibodies was higher in younger (up to 60% for 20 year olds) as opposed to older (20% for >50 years) male and female donors. Anti-PEG IgG concentrations were negatively associated with donor age in both females (p = 0.0073) and males (p = 0.026). Both anti-PEG IgM and IgG strongly bound PEGylated medicines. The described assay can assist in the elucidation of the impact of anti-PEG antibodies on the safety and therapeutic efficacy of PEGylated medicines.

AB - Polyethylene glycol (PEG) is a biocompatible polymer that is often attached to therapeutic molecules to improve bioavailability and therapeutic efficacy. Although antibodies with specificity for PEG may compromise the safety and effectiveness of PEGylated medicines, the prevalence of pre-existing anti-PEG antibodies in healthy individuals is unclear. Chimeric human anti-PEG antibody standards were created to accurately measure anti-PEG IgM and IgG antibodies by direct ELISA with confirmation by a competition assay in the plasma of 1504 healthy Han Chinese donors residing in Taiwan. Anti-PEG antibodies were detected in 44.3% of healthy donors with a high prevalence of both anti-PEG IgM (27.1%) and anti-PEG IgG (25.7%). Anti-PEG IgM and IgG antibodies were significantly more common in females as compared to males (32.0% vs 22.2% for IgM, p < 0.0001 and 28.3% vs 23.0% for IgG, p = 0.018). The prevalence of anti-PEG IgG antibodies was higher in younger (up to 60% for 20 year olds) as opposed to older (20% for >50 years) male and female donors. Anti-PEG IgG concentrations were negatively associated with donor age in both females (p = 0.0073) and males (p = 0.026). Both anti-PEG IgM and IgG strongly bound PEGylated medicines. The described assay can assist in the elucidation of the impact of anti-PEG antibodies on the safety and therapeutic efficacy of PEGylated medicines.

UR - http://www.scopus.com/inward/record.url?scp=84994051853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994051853&partnerID=8YFLogxK

U2 - 10.1021/acs.analchem.6b03109

DO - 10.1021/acs.analchem.6b03109

M3 - Article

VL - 88

SP - 10661

EP - 10666

JO - Analytical Chemistry

JF - Analytical Chemistry

SN - 0003-2700

IS - 21

ER -